BioPh Summit China 2015

Concurrently held with the expo, BioPh Summit China 2015 will focus on optimizing the biopharmaceutical industry. It is an unparalleled platform for regulatory updates and analysis, technical presentations, technology transfer project promotions, business connections, and partnership development, through a series of networking opportunities including speed name card exchanging, project match making and private meetings.

Key Words

Chinese Pharmacopoeia 2015

FDA Approval Obstacles

Blockbuster Biologics

Biobetters

Simplified Biosimilar Registration by SFDA

Mergers &Acquisitions in Global Pharma Markets

SME Business Expansion

Antibody Drug Conjugate (ADC) Technology

Quality by Design (QbD)

From Experimental Level to Mass Production

Conference Structure

Module One: Biopharma Regulatory Updates

Module Two: Global Biopharma Market Outlook

Module Three: Cutting Edge Biopharma Technology Solutions

Part Of Speakers：

l  Mingyang Liao, chief expert ,Beijing Institute For Drug Control

l  Mingde Xia, Senior Director, Johnson & Johnson

l  Rong Chen, Head of Regulatory Center of Excellence, GSK

l  Mia Wang, Group Leader, Genentech, USA

l  Joe Zhang, Center of Medical and Translational Sciences, CP Guojian Pharm

l  Maykin Ho, Advisory Director, Goldman Sachs (Asia) LLC

l  Scott M Wheelwright PhD, Principal Consultant, Complya Asia